
Samrat Pharmachem Ltd is Rated Strong Sell
2026-07-10 10:10:30Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Samrat Pharmachem Ltd is Rated Strong Sell
2026-06-29 10:10:26Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 June 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Samrat Pharmachem Ltd is Rated Strong Sell
2026-06-17 10:10:37Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 17 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleAre Samrat Pharmachem Ltd latest results good or bad?
2026-06-01 19:22:21Samrat Pharmachem Ltd's latest financial results for Q4 FY26 reveal significant operational challenges. The company reported net sales of ₹71.77 crores, reflecting a modest year-on-year growth of 0.80% and a sequential increase of 13.15% from the previous quarter. However, this top-line growth is overshadowed by a substantial net loss of ₹2.04 crores, marking a severe decline in profitability compared to the same quarter last year. The operating profit margin turned deeply negative at -1.73%, which is a notable deterioration from the positive margins recorded in previous years. This operational distress is further highlighted by the company's profit before tax, which fell to negative ₹1.87 crores, indicating a significant operational reversal. The PAT margin also collapsed to -2.84%, down from -0.56% in the prior year. The financial performance indicates that while revenue has shown some growth, the compa...
Read full news article
Samrat Pharmachem Q4 FY26: Steep Losses Trigger 16% Stock Crash
2026-06-01 11:00:47Samrat Pharmachem Limited reported a disastrous fourth quarter for FY2026, posting a net loss of ₹2.04 crores compared to a loss of ₹0.40 crores in the same quarter last year—a staggering deterioration of 410.00%. The micro-cap pharmaceutical chemicals manufacturer, with a market capitalisation of ₹65.00 crores, saw its stock plummet 15.63% to ₹210.00 on June 01, 2026, as investors reacted to the alarming financial performance that marked the company's worst quarterly showing in recent history.
Read full news article
Samrat Pharmachem Ltd is Rated Strong Sell
2026-05-29 10:10:22Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 29 May 2026, providing investors with the latest insights into its performance and prospects.
Read full news article
Samrat Pharmachem Ltd is Rated Strong Sell
2026-05-18 10:10:16Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 Aug 2025. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 18 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Samrat Pharmachem Ltd is Rated Strong Sell
2026-05-05 10:10:17Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Aug 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 May 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trend, and technical outlook.
Read full news article
Samrat Pharmachem Ltd is Rated Strong Sell
2026-04-21 10:10:18Samrat Pharmachem Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 August 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 21 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Read full news articleCompliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
17-Jul-2026 | Source : BSECertificate under Reg. 74(5) of SEBI (DP) Regulations for the quarter ended 30th June 2026
Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
17-Jul-2026 | Source : BSEAppointment of Statutory Auditors for the company from 34th Annual General Meeting to 39th Annual General Meeting
Board Meeting Intimation for Notice Of Board Meeting For Un-Audited Financial Results For The Quarter Ended June 30 2026
30-Jun-2026 | Source : BSESamrat Pharmachem Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Approval of Un-Audited Financial Results for the quarter ended June 30 2026
Corporate Actions
14 Aug 2026
Samrat Pharmachem Ltd has declared 10% dividend, ex-date: 18 Sep 25
No Splits history available
No Bonus history available
No Rights history available






